Evaluation of the quality of RNA extracted from archival FFPE glioblastoma and epilepsy surgical samples for gene expression assays by Haynes, Harry R. et al.
                          Haynes, H. R., Killick-Cole, C. L., Hares, K. M., Redondo, J., Kemp, K. C.,
Moutasim, K. A., ... Kurian, K. M. (2018). Evaluation of the quality of RNA
extracted from archival FFPE glioblastoma and epilepsy surgical samples for
gene expression assays. Journal of Clinical Pathology, 71(8), 695-701.
https://doi.org/10.1136/jclinpath-2017-204969
Peer reviewed version
Link to published version (if available):
10.1136/jclinpath-2017-204969
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via BMJ at http://jcp.bmj.com/content/early/2018/02/20/jclinpath-2017-204969.info. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  
An evaluation of the quality of RNA extracted from archival FFPE 
glioblastoma and epilepsy surgical samples for gene expression assays 
 
Haynes HR 1,2, Killick-Cole CL3, Hares KM 4, Redondo J 4, Kemp KC 4, Moutasim KA 5, 
Faulkner C 6, Wilkins A 4, Kurian KM 1 
 
1. Brain Tumour Research Group, Institute of Clinical Neurosciences, University of Bristol, UK 
2. Department of Cellular Pathology, North Bristol NHS Trust, Bristol, UK 
3. Functional Neurosurgery Research Group, Institute of Clinical Neurosciences, University of Bristol, UK 
4. MS and Stem Cell Research Group, Institute of Clinical Neurosciences, University of Bristol, UK 
5. Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK 
6. Bristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK 
 
Jan 2017  
Corresponding author: 
Harry Haynes 
harryrhaynes@doctors.org.uk 
 
 
 
 
Word count: 3226 
 
  
Haynes et al. FFPE qPCR 2017, v3 FINAL  
 
 - 2 - 
 
ABSTRACT (247 words) 
Aims: Histopathological tissue samples are being increasingly utilised as sources of nucleic 
acids in molecular pathology translational research.  This study investigated the suitability of 
glioblastoma and control CNS formalin fixed paraffin embedded (FFPE) tissue-derived RNA 
for gene expression analyses. 
Methods: Total RNA was extracted from control (temporal lobe resection tissue) and 
glioblastoma FFPE tissue samples.  RNA purity (260/280 ratios) was determined and RNA 
integrity number (RIN) analysis performed.  RNA was subsequently used for RT-qPCR for two 
reference genes, 18S and GAPDH. 
Results: Reference gene expression was equivalent between control and glioblastoma tissue 
when using RNA extracted from FFPE tissue, which has key implications for biological 
normalisation for CNS gene expression studies. There was a significant difference between 
the mean RIN values of control and glioblastoma FFPE tissue.  There was no significant 
correlation between 260/280 or RIN values vs total RNA yield.  The age of the tissue blocks 
did not influence RNA yield, fragmentation or purity.  There was no significant correlation 
between RIN or 260/280 ratios and mean cycle threshold (Ct) for either reference gene.  
Conclusions: This study showed that routinely available CNS FFPE tissue is suitable for RNA 
extraction and downstream gene expression studies, even after 60 months of storage. 
Substantial RNA fragmentation associated with glioblastoma and control FFPE tissue blocks 
did not preclude downstream RT-qPCR gene expression analyses.  Cross validation with both 
archival and prospectively collated FFPE specimens is required to further demonstrate that 
CNS tissue blocks can be utilised in novel translational molecular biomarker studies. 
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INTRODUCTION 
Gliomas are the most common primary CNS tumours, with an incidence of 6.6 per 100,000 
individuals per year 1.  Approximately 50% of newly diagnosed gliomas are glioblastomas 2.  
The median patient survival is approximately 15 months in the setting of a clinical trial 3,4 and 
only 12 months using the current established treatment regimens 1,5. 
Histopathological diagnosis of glioblastoma is dependent on formalin-fixed paraffin embedded 
(FFPE) tissue obtained from a biopsy or surgical resection. Despite a number of practical 
issues regarding using this diagnostic tissue for research, the number of molecular studies 
incorporating FFPE material is increasing 6.  
 
The high quality morphological information that FFPE tissue provides facilitates accurate 
macro- and microdissection of areas of interest. This means that with downstream nucleic acid 
purification and enrichment, histopathological abnormalities (for example the malignant 
transformation of a cellular population or subpopulation), can be interrogated using molecular 
tools 7. This approach has been widely used in the discovery phase of biomarker investigation 
for large-scale validation and for subsequent implementation into routine clinical practice 8. 
 
Tumour tissue is a heterogeneous milieu of non-transformed cells, immune cells, stromal cells 
and areas of necrosis in which the neoplastic cells may only represent a small proportion.  
Therefore, accurate assessment of tumour cell composition by expert histopathologists based 
upon morphological features is essential.  This assessment can then guide nucleic acid 
extraction for subsequent molecular analyses. This may be done manually, using pre-marked 
haematoxylin and eosin (H&E) sections to guide dissecting areas of tissue (i.e. 
macrodissection) or using automated laser capture microdissection 9, with the emerging 
possibility of single cell analysis 10.  Techniques such as expression microdissection may allow 
for enrichment of extracted cell populations by immunohistochemical labelling 11.  In contrast, 
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the use of fresh frozen (unfixed) tissue is associated with the homogenisation of tissue 
samples (for downstream protein, DNA or RNA extraction), a bulk analysis approach in which 
the input cellular material may be sub-optimally (or blindly) selected. 
 
RNA isolated from FFPE tissue is often of lower quality than that obtained from fresh frozen 
tissue, frequently showing evidence of degradation, fragmentation and reduced assay 
efficiency 12.  Nucleic acid quantity and quality may also be dependent on the extraction 
method utilised 13,14.  It is therefore important that total RNA extracted from FFPE samples is 
adequately assessed before being assayed in downstream molecular applications. 
 
This study examined the applicability of FFPE tissue for RNA extraction for subsequent 
molecular expression analyses in the context of glioblastoma.  Quality control (QC) metrics 
were assessed for FFPE tissue-derived RNA for glioblastoma and (control) epilepsy resection 
specimens. 
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MATERIALS AND METHODS 
Study samples 
IDH1[R132H]-wildtype (primary) glioblastoma FFPE surgical specimens 15, diagnosed 
according to WHO diagnostic criteria were obtained from the Brain Tumour Bank Southwest, 
UK.  FFPE tissue samples from histologically normal anterior temporal lobe surgical resections 
were used as controls. Control tissue samples were provided under BrainUK ethical approval 
(14/008, 15/017).  
 
Tumour FFPE sample area selection for macrodissection 
Two histopathologist researchers (HRH & KMK) reviewed H&E stained FFPE glioblastoma 
sections and marked areas containing only tumour cells.  Any areas containing extensive 
tissue necrosis, haemorrhage, microvascular proliferation or histologically normal cerebral 
cortex were marked for exclusion from downstream total RNA extraction.  
 
RNA extraction from FFPE tissue sections 
Tissue blocks were sectioned at 5m and stored in the absence of light at ambient temperature 
for a maximum of 21 days. Total RNA was extracted from either whole control tissue (n=17; 
x10 5m FFPE unstained sections) or macrodissected regions of glioblastoma tissue (n=48; 
x10 5m FFPE unstained sections).  Total RNA was extracted using an EZNA FFPE RNA kit 
(OmegaBio-tek) including a gDNA elimination spin column step, as previously described 16. 
Purified total RNA was eluted into RNase-free water. RNA was stored at -80oC until use.   
 
RNA Quality and Quantity 
RNA concentration and 260/280 ratios were determined using a Nanodrop 1000 UV 
spectrophotometer (ThermoScientific).  RNA integrity number (RIN) analysis was performed 
using an Agilent 2100 Bioanalyser and RNA 6000 LabChip kit with Agilent 2100 Expert 
software (Agilent Technologies).  260/280 ratios and RIN were determined for all control 
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samples (n=17) and a subset of glioblastoma samples (selected randomly n=29). Two RIN 
values were not detected using the Agilent 2100 Instrument in the glioblastoma cohort.  Total 
RNA was reverse transcribed to cDNA using a Clontech TaKaRa PrimeScript 1st strand cDNA 
Synthesis Kit (TaKaRa Bio) following the manufacturer’s protocol. 
 
Linear dynamic range (LDR) and efficiency of RT-qPCR reactions 
The linear dynamic range (LDR) for each Taqman assay on demand (AOD) was investigated 
prior to gene expression analyses.  Taqman fast gene expression mastermix (Applied 
Biosystems) was used. The LDR of each AOD was assessed using a standard curve method, 
utilising serial dilutions of cDNA template. The log of cDNA starting quantity against the cycle 
threshold (Ct) value obtained during amplification was plotted for each dilution.  Experiments 
were performed in triplicate using the StepOnePlus Real-Time PCR system and StepOne 
software v2.1 (Applied Biosystems), which provided an automated output to fit the equation of 
the linear regression line and the coefficient of determination (R2).  Two representative cDNA 
samples from each of the control and glioblastoma subsets of the FFPE cohort were used for 
this optimisation. 
 
Reverse transcription quantitative real-time PCR (RT-qPCR) 
RT-qPCR was performed with a StepOnePlus instrument with Taqman Fast Gene Expression 
Mastermix (both Applied Biosytems) and AOD gene expression products for GAPDH 
(Hs02758991_g1) (amplicon length, 93 bp) and 18S (Hs03003631_g1) (amplicon length, 
69 bp) (Taqman MGB probes, FAM dye-labelled; Applied Biosytems). Experiments were 
performed in triplicate.  Relative gene expression was analysed with the 2–ΔΔCt method 17 and 
the geomean calculated for each group.  No-template control (1l nuclease-free water) and 
RT- (gDNA contamination) control samples were included in each PCR run.  The amplification 
baseline and threshold were automatically calculated by the StepOne software.  
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Statistical Analysis 
Data normality was tested using the Kolmogorov-Smirnov and the D’Agostino and Pearson 
omnibus normality tests.  A Mann-Whitney test or unpaired t-test was used to compare the 
parameters RIN, age of block and 260/280 ratios in control versus disease tissue.  Correlation 
analysis was performed using Pearson correlation coefficient (parametric data) or Spearman 
rank correlation (non-parametric data) as appropriate.  All statistical tests were two-tailed.  
Differences at p<0.05 were considered statistically significant.  Statistical tests were performed 
using GraphPad Prism v5 for Windows (GraphPad). 
 
 
RESULTS 
The linear dynamic range (LDR) of RT-qPCR AOD 
AOD optimisation was performed for the reference genes GAPDH and 18S by generating a 
standard curve prior to downstream quantification of relative gene expression.  The R2 for both 
GAPDH and 18S was >0.980 (Figure 1a&b), indicative of a strong linear relationship between 
absolute starting template and assay output.  Downstream relative gene expression studies 
were performed using RT-qPCR and starting cDNA concentrations corresponding to the 
median cDNA concentration within the LDR for each AOD. 
 
Reference gene expression in control versus glioblastoma FFPE tissue  
RT-qPCR was performed on cDNA generated from FFPE control and glioblastoma tissue 
blocks.  There was no significant difference in the expression of the reference gene GAPDH 
in the glioblastoma samples compared to control samples when normalised to 18S mRNA 
expression (p=0.576; Figure 2a).  Similarly, there was no significant difference in the 
expression of the reference gene 18S in glioblastoma samples compared to control samples, 
when normalised to GAPDH (p=0.575; Figure 2b). 
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Analysis of RNA quality control metrics in control and glioblastoma FFPE tissue 
samples 
The mean RIN in the control FFPE tissue cohort was 2.2 (range: 1.3-2.7).  The mean RIN in 
the glioblastoma FFPE tissue cohort was 1.7 (range: 1.0-2.7).  There was a significant 
difference in the RIN value between these 2 groups (p=0.008) (Figure 3a).  The mean age of 
the blocks (months) in the control cohort was 24.9 (range: 3-60).  The mean age of the blocks 
(months) in the glioblastoma cohort was 32.9 (range: 14-55).  There was no significant 
difference in the age of the blocks between these 2 groups (p=0.097) (Figure 3b).  The mean 
260/280 ratio in the control cohort was 1.94 (range: 1.63-2.05).  The mean 260/280 ratio in 
the glioblastoma cohort was 1.95 (range: 1.63-2.26). There was no significant difference in 
the 260/280 ratio between these 2 groups (p=0.715) (Figure 3c).  The mean percentage 
tumour (by area of total tissue per slide) in the glioblastoma FFPE tissue cohort alone was 
61% (range: 15-100%).   
There was no statistically significant correlation between total RNA yield (ng/μl) vs RIN in the 
control and glioblastoma FFPE tissue blocks as a single group (p=0.250) (Figure 
4a).  Furthermore, there was no statistically significant correlation between total RNA yield 
(ng/μl) vs 260/280 ratio in the control and glioblastoma FFPE tissue blocks as a single group 
(p=0.172) (Figure 4b).    
There was no significant correlation between age of the block vs RIN in the control or 
glioblastoma FFPE tissue blocks (p=0.249, p=0.983 respectively) (Figure 5a&b) and no 
significant correlation between age of the block vs total RNA yield (ng/μl) in the control or 
glioblastoma FFPE tissue blocks (p=0.268, p=0.252; respectively) (Figure 5c&d); although a 
non-significant overall negative trend was noted, particularly for the glioblastoma FFPE tissue 
blocks.  There was no significant correlation between age of the block vs 260/280 ratios in the 
control or glioblastoma FFPE tissue blocks (p=0.384, p=0.133 respectively) (Figure 6a&b).   
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There was no significant correlation between RIN vs (raw) mean Ct values for GAPDH or 18S 
mRNA expression values in the control and glioblastoma FFPE tissue blocks combined 
(p=0.119, p=0.057 respectively) (Figure 7a&b), although a non-significant overall negative 
trend was noted, particularly for mean 18S mRNA expression values (Figure 7b). There was 
a statistically significant negative correlation between 260/280 ratios vs (raw) mean Ct values 
for GAPDH and 18S mRNA expression values in the control and glioblastoma FFPE tissue 
blocks combined (p=0.013, p=0.006 respectively) (Figure 7c&d).   
 
 
DISCUSSION 
 
It is essential that new tools are developed that better delineate the biological variants of 
glioblastoma. However, to date molecular assays that determine which newly diagnosed 
glioblastoma patients may respond to standard or experimental adjuvant therapies have 
proven elusive.  Without a more finessed approach, treatment targets may be missed and 
patients given toxic therapies not sufficiently targeted to their tumour subtype 18.  In addition, 
molecular profiling can facilitate the identification of personalised prognostic features which 
can be used for patient stratification in clinical trial design, to ensure balance in the arms of 
randomised control trials of novel glioblastoma therapies 19.   
Although data from targeted gene panel massive parallel sequencing approaches are already 
used to guide clinical decision making at molecular tumour boards 20, RNA expression analysis 
is likely to continue to have significant utility, complementing high-throughput sequencing of 
gDNA 21,22.  Gene expression studies have traditionally been carried out on nucleic acids 
extracted from fresh (snap) frozen tissue.  More recently however FFPE tissue is being 
increasingly utilised due to its abundance in clinical diagnostic pathology archives and a 
growing interest in how to best control for the limitations inherent in FFPE based genetic 
studies 23–25.  For example, the Oncotype DX clinical assay, which uses FFPE-derived RNA 
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in RT-qPCR applications, is routinely used to guide adjuvant treatment decisions for breast 
cancer patients 26.  This use of RNA expression analysis adds predictive value to established 
clinicopathological and protein expression variables and is applicable to routinely available 
FFPE specimens.  Although similar approaches have been investigated for glioblastoma 27,28, 
to date none have been extensively cross validated or achieved widespread acceptance.  In 
order for this powerful approach to be more widely implemented, a better understanding of the 
limiting factors in the molecular investigation of FFPE glioblastoma (and control) tissue-
derived nucleic acids is required. 
In this study, the quality and quantity of RNA extracted from glioblastoma and control FFPE 
tissue was examined.  Normalisation of RT-qPCR data to GAPDH or 18S is commonly used 
in gene expression studies, as their expression is considered to be ubiquitous in the entire cell 
population present in a tissue sample.  This study demonstrated that there was no significant 
difference between GAPDH and 18S mRNA expression between control and glioblastoma 
samples, strongly suggesting that their expression is consistent between the two tissue 
cohorts.  This is an important consideration when selecting reference genes for biological 
normalisation to perform quantitative mRNA studies comparing CNS tissue cohorts 29,30 and 
requires further cross validation with independent tissue sources. 
During the optimisation of AOD used for downstream RT-qPCR analysis, GAPDH and 18S 
reference genes both returned high regression coefficient variables, suggesting low variability 
between technical replicates and indicating that the PCR amplification efficiency was the same 
regardless of the starting template copy number. This is appropriate for studies on RNA 
extracted from FFPE tissue where the starting template amount may vary.  
 
In this study, a single RNA FFPE extraction kit and protocol was used to extract total RNA 
from both primary glioblastoma and histologically normal anterior temporal lobe surgical 
resection samples derived from a single diagnostic archive.  QC metrics were applied to the 
extracted total RNA prior to reverse transcription.  Glioblastoma surgical samples that were 
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subjected to RIN analysis had significantly lower RIN values compared to control tissue.  It is 
likely that the lower RIN values obtained for the glioblastoma cohort occurred due to increased 
levels of apoptosis and necrosis occurring in the tumour tissue. Although substantial RNA 
degradation was noted, the mean RIN and RIN range was comparable to that found in 
previously published studies which utilised RNA extracted from FFPE tissue samples, both for 
human glioma samples 31,32 and other common cancers 13,33.  It is increasingly recognised that 
low RIN values (i.e. 1.0) do not preclude successful outcomes in gene expression studies 34,35.   
The RIN and 260/280 ratios, pooled across both control and glioblastoma FFPE tissue blocks, 
showed no significant correlation with total RNA yield, suggesting that neither fragmentation 
of extracted RNA nor its purity impacted on downstream quantity measurements.  This is in 
keeping with previous reports which suggest that the quality and quantity of RNA extracted 
from FFPE tissues are likely to be independent factors: RNA quality being affected primarily 
by preanalytical factors and RNA quantity by the extraction technique employed 36.  This effect 
has also been reported in snap-frozen CNS tissue (non-neoplastic) cohorts 37.   
In both control and glioblastoma tissue,  RIN values did not correlate significantly with the age 
of the blocks, a finding in keeping with previously published work on FFPE breast carcinoma 
samples 33.   Similarly, both total RNA yield and 260/280 ratios were not found to be correlated 
with the age of the tissue blocks.  This has important implications for future investigations 
which may utilise retrospective FFPE tissue cohorts for translational molecular studies in 
which longer clinical follow up is required. 
There was no significant correlation between RIN values and raw Ct values obtained for the 
reference genes GAPDH and 18S, in keeping with previous findings 38.  It is noteworthy that 
260/280 ratios did, however, show a negative correlation with raw GAPDH and 18S Ct values.  
A 260/280 ratio of 2.0 is widely accepted as “pure” for RNA samples 39: the lower values noted 
in this study are likely to be due to contamination by materials present in the FFPE sections 
or reagents utilised during RNA extraction from the FFPE tissue.  The increasing raw Ct values 
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noted to correlate with the lower 260/280 ratios may have occurred due to a decrease in PCR 
amplification efficiency by inhibitory contaminants.  This effect is predicted to occur for both 
any putative genes of interest and the reference genes described herein and is therefore less 
likely to influence downstream relative gene expression outputs.   
In summary, this study showed that routinely available FFPE CNS tissue samples are suitable 
for RNA extraction and downstream gene expression studies, even after 60 months of storage.  
In addition, it was shown that substantial RNA fragmentation associated with glioblastoma and 
control cortex FFPE tissue blocks does not preclude successful downstream RT-qPCR gene 
expression analyses.  Cross validation with both archival and prospectively collated FFPE 
specimens is required to further demonstrate that CNS tissue blocks can be utilised in novel 
translational molecular biomarker studies. 
 
 
Key messages: 
1.Careful quality control of nucleic acids extracted from FFPE tissues is key to 
successful molecular analyses. 
2. Prolonged FFPE tissue storage may not affect the quality or quality of RNA extracted. 
3.Substantial RNA fragmentation associated with FFPE tissue does not influence 
quantitative outputs in appropriately designed RT-qPCR analyses. 
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Figure 1: Representative amplification plot and standard curve. 
Six-fold dilutions of cDNA were used to optimise assays on demand (AOD).  (A) Upper panel 
shows the GAPDH amplification plot, with (B) Corresponding standard curve in the lower 
panel. Standard curves were constructed for each AOD by plotting raw Ct values vs log (input 
cDNA). Similar results were obtained for 18S. 
 
Figure 2:  Reference gene expression by RT-qPCR using FFPE extracted RNA 
A) GAPDH mRNA expression was examined in FFPE samples of control cortex (n = 17) and 
glioblastoma (n = 48) by RT-qPCR, normalised to the reference gene 18S.  (B) 18S mRNA 
expression was examined in FFPE samples of control cortex (n = 17) and glioblastoma (n = 
48) by RT-qPCR, normalised to the reference gene GAPDH.  The geometric mean and 95% 
confidence interval are shown on a logarithmic scale (to base2). The test statistic is a Mann–
Whitney test two-tailed p-value. ns, non-significant. GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase. 18S, 18S ribosomal RNA. 
 
Figure 3:  RIN values, age of FFPE tissue blocks and RNA 260/280 values: control vs 
glioblastoma FFPE samples. 
(A) RIN values for RNA extracted from FFPE control (n=17) vs glioblastoma (n=27, 2 missing 
RIN values) samples.  (B) Age of the tissue block (months) used for RNA extraction, control 
(n=17) vs glioblastoma (n=29) samples.  (C) 260/280 ratios for RNA extracted from FFPE 
control (n=17) vs glioblastoma (n=29) samples. The test statistic is a Mann–Whitney test two-
tailed p-value (A and C) or unpaired t-test two-tailed p-value (B).  Error bars show SEM.  ns, 
non-significant; ** p<0.01.  
 
Figure 4:  RIN values vs total RNA yield and 260/280 ratios vs total RNA yield 
(A) RIN values for RNA extracted from FFPE samples vs total RNA yield (n=44, 2 missing RIN 
values).  (B) 260/280 ratios for RNA extracted from FFPE samples vs total RNA yield (n=46).  
rs; Spearman’s rank (nonparametric) correlation coefficient.  Dotted lines; 95% CI.  x axis 
shown on a logarithmic scale (to base2) (A&B). 
 
Figure 5: RIN values and total RNA yield vs age of control and glioblastoma FFPE 
blocks. 
(A) RIN values for RNA extracted from FFPE samples vs age of control FFPE blocks (months) 
(n=17).  (B) RIN values for RNA extracted from FFPE samples vs age of glioblastoma FFPE 
blocks (months) (n=27, 2 missing RIN values).  (C) Total RNA yield vs age of control FFPE 
blocks (months) (n=17).  (D) Total RNA yield vs age of glioblastoma FFPE blocks (months) 
(n=29).  rs; Spearman’s rank (nonparametric) correlation coefficient; Pearson r, Pearson 
(parametric) correlation coefficient.  Dotted lines; 95% CI. 
 
Figure 6: 260/280 ratios vs age of control and glioblastoma FFPE tissue blocks 
(A) 260/280 values for RNA extracted from FFPE samples vs age of control FFPE blocks 
(months) (n=17).  (B) 260/280 values for RNA extracted from FFPE samples vs age of 
glioblastoma FFPE blocks (months) (n=29).  rs; Spearman’s rank (nonparametric) correlation 
coefficient.  Dotted lines; 95% CI. 
 
Figure 7: RIN values and 260/280 ratios vs (raw) mean Ct values 
RIN values for RNA extracted from FFPE samples vs (A) GAPDH mean PCR Ct values (n=44) 
and (B) 18S mean PCR Ct values (n=44).  260/280 ratios for RNA extracted from FFPE 
samples vs (C) GAPDH mean PCR Ct values (n=46) and (D) 18S mean PCR Ct values (n=46). 
rs; Spearman’s rank (nonparametric) correlation coefficient; Pearson r, Pearson (parametric) 
correlation coefficient.  Dotted lines; 95% CI. 
